SOUTH SAN FRANCISCO, Calif.,
Sept. 28, 2020 /PRNewswire/ -- Akero
Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology
company developing transformational treatments for patients with
non-alcoholic steatohepatitis (NASH) and other serious metabolic
disorders, today announced that Andrew
Cheng, chief executive officer of Akero, will present
virtually at the H.C. Wainwright 4th Annual NASH
Conference on Monday, October 5, 2020
at 12:00 p.m. E.T.
A live webcast of the presentation and Q&A will be available
through the investor relations section of the Company's website at
www.akerotx.com. Following the live webcast, an archived replay
will be available on the Company's website.
About Akero Therapeutics
Akero is a cardio-metabolic
NASH company dedicated to reversing the escalating NASH epidemic by
developing pioneering medicines designed to restore metabolic
balance and improve overall health of NASH patients. The Company's
lead product candidate, AKR-001, is currently being evaluated in an
ongoing Phase 2a clinical trial. Akero Therapeutics is
headquartered in South San
Francisco, CA. For more information, please visit
www.akerotx.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/akero-therapeutics-to-present-at-hc-wainwrights-4th-annual-nash-virtual-investor-conference-301139211.html
SOURCE Akero Therapeutics, Inc.